0001493152-24-010741.txt : 20240321 0001493152-24-010741.hdr.sgml : 20240321 20240321085038 ACCESSION NUMBER: 0001493152-24-010741 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240319 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12555 FILM NUMBER: 24769625 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 19, 2024

PROTAGENIC THERAPEUTICS, INC.

(Exact name of Company as specified in its charter)

Delaware

001-12555

06-1390025

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

149 Fifth Avenue, Suite 500, New York, NY		10010
(Address of principal executive offices)		(Zip Code)

212-994-8200

(Company’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

Protagenic Therapeutics, Inc. Common Stock		PTIX		Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants		PTIXW		Nasdaq

Item 7.01 Regulation FD Disclosure.

On March 21, 2024, the Company issued a press release announcing resolution of the Company’s outstanding Nasdaq deficiency notice. A copy of the press release is furnished with this report as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1 attached hereto, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.

Item 8.01 Other Events.

On March 19, 2024, the Company received written notice from the Nasdaq Listing Qualifications Department (the “Staff”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) by maintaining a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the last ten consecutive trading days, from March 5, 2024 to March 18, 2024, and that this matter is now closed. As previously reported, on November 21, 2023, Nasdaq notified the Company that, the closing bid price for the Company’s common stock had been below the minimum $1.00 per share requirement for 30-consecutive business in violation of the Minimum Bid Price Requirement.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description

99.1		Press release - “*Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice”*

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTAGENIC THERAPEUTICS, INC.

Date: March 21, 2024	By:	/s/ Alexander K. Arrow
	Name:	Alexander K. Arrow
	Title:	Chief Financial Officer

3

EX-99.1 2 ex99-1.htm

Exhibit 99.1

FOR IMMEDIATE RELEASE

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice

NEW YORK, March 21, 2024 — Protagenic Therapeutics, Inc. (Nasdaq: PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.

On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).

About Protagenic Therapeutics, Inc.:

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.

About PT00114:

PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.

Forward-Looking Statements:

This press release contains forward-looking statements concerning Protagenic Therapeutics’ product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.

Company Contact:

Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com

Investor Relations Contact:

Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ptix-20240319.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ptix-20240319_def.xml XBRL DEFINITION FILE EX-101.LAB 6 ptix-20240319_lab.xml XBRL LABEL FILE Class of Stock [Axis] Protagenic Therapeutics, Inc. Common Stock Protagenic Therapeutics, Inc. Common Stock Warrants Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ptix-20240319_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 19, 2024
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 19, 2024
Entity File Number	001-12555
Entity Registrant Name	Protagenic Therapeutics, Inc.\new
Entity Central Index Key	0001022899
Entity Tax Identification Number	06-1390025
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	149 Fifth Avenue
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	212
Local Phone Number	994-8200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Protagenic Therapeutics, Inc. Common Stock
Title of 12(b) Security	Protagenic Therapeutics, Inc. Common Stock
Trading Symbol	PTIX
Security Exchange Name	NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants
Title of 12(b) Security	Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol	PTIXW
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 22 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://protagenic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60540-EntityEmergingGrowthCompany-Missing] Submission type 8-K should have a non-empty value for EntityEmergingGrowthCompany in the Required Context. form8-k.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - form8-k.htm 21 form8-k.htm ptix-20240319.xsd ptix-20240319_def.xml ptix-20240319_lab.xml ptix-20240319_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PTIX", "nsuri": "http://protagenic.com/20240319", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ptix-20240319.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "ptix-20240319_def.xml" ] }, "labelLink": { "local": [ "ptix-20240319_lab.xml" ] }, "presentationLink": { "local": [ "ptix-20240319_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://protagenic.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://protagenic.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "PTIX_ProtagenicTherapeuticsInc.CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20240319", "localname": "ProtagenicTherapeuticsInc.CommonStockMember", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Protagenic Therapeutics, Inc. Common Stock" } } }, "auth_ref": [] }, "PTIX_ProtagenicTherapeuticsInc.CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://protagenic.com/20240319", "localname": "ProtagenicTherapeuticsInc.CommonStockWarrantsMember", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Protagenic Therapeutics, Inc. Common Stock Warrants" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://protagenic.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001493152-24-010741-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-010741-xbrl.zip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end XML 20 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001022899 2024-03-19 2024-03-19 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2024-03-19 2024-03-19 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2024-03-19 2024-03-19 iso4217:USD shares iso4217:USD shares false 0001022899 Protagenic Therapeutics, Inc.\new 8-K 2024-03-19 DE 001-12555 06-1390025 149 Fifth Avenue Suite 500 New York NY 10010 212 994-8200 false false false false Protagenic Therapeutics, Inc. Common Stock PTIX NASDAQ Protagenic Therapeutics, Inc. Common Stock Warrants PTIXW NASDAQ